MEM Stock Overview
Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Memphasys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.006 |
| 52 Week High | AU$0.014 |
| 52 Week Low | AU$0.004 |
| Beta | 0.97 |
| 11 Month Change | -25.00% |
| 3 Month Change | -33.33% |
| 1 Year Change | -57.14% |
| 33 Year Change | -93.68% |
| 5 Year Change | -90.16% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Memphasys (ASX:MEM) Using Too Much Debt?
Jun 19
Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Mar 01Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Jun 13Does Memphasys (ASX:MEM) Have A Healthy Balance Sheet?
Jun 20Is Memphasys (ASX:MEM) A Risky Investment?
Feb 28Memphasys (ASX:MEM) Is Making Moderate Use Of Debt
Sep 01Will Memphasys (ASX:MEM) Spend Its Cash Wisely?
Jan 07Shareholder Returns
| MEM | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 20.0% | -6.0% | 0.9% |
| 1Y | -57.1% | 8.8% | 17.7% |
Return vs Industry: MEM underperformed the Australian Life Sciences industry which returned 8.8% over the past year.
Return vs Market: MEM underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| MEM volatility | |
|---|---|
| MEM Average Weekly Movement | 22.9% |
| Life Sciences Industry Average Movement | 11.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: MEM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: MEM's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Ali | www.memphasys.com |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port.
Memphasys Limited Fundamentals Summary
| MEM fundamental statistics | |
|---|---|
| Market cap | AU$8.67m |
| Earnings (TTM) | -AU$4.44m |
| Revenue (TTM) | AU$1.09m |
8.0x
P/S Ratio-2.0x
P/E RatioIs MEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEM income statement (TTM) | |
|---|---|
| Revenue | AU$1.09m |
| Cost of Revenue | AU$115.46k |
| Gross Profit | AU$974.38k |
| Other Expenses | AU$5.42m |
| Earnings | -AU$4.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | 89.41% |
| Net Profit Margin | -407.58% |
| Debt/Equity Ratio | 64.5% |
How did MEM perform over the long term?
See historical performance and comparison